Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
The Center for Prevention of Progression is the first-of-its-kind clinic for patients with precursor conditions of hematologic malignancies. As part of the Hematologic Oncology Treatment Center, the Center for Prevention of Progression builds on Dana-Farber's past and ongoing research efforts for precursor conditions. The clinic evaluates individuals
diagnosed with these conditions or at high risk for disease development, and works with patients to manage their risk of disease progression.
As with many solid tumors, some blood cancers are preceded by precursor conditions. These conditions are sometimes found through routine blood tests, but often remain undiagnosed. In the Center for Prevention of Progression, we strive to detect blood cancer precursor conditions and intervene early to prevent blood cancers from developing.
Precursor blood conditions include:
Certain individuals are at higher risk for these conditions and should consider screening and counseling at the Center. These include:
Patients are cared for by a multidisciplinary team that harnesses Dana-Farber's leadership and expertise in hematologic malignancies, genetic risk and prevention. This includes hematologists/oncologists who specialize in a patient's specific precursor
condition, as well as specialists in genetic risk and prevention, genetic counseling, psychosocial support, and other specialties as needed.
Center for Prevention of Progression Appointments
Clinical Trials Questions?
Irene Ghobrial, MD, discusses precursor hematologic conditionsDr. Ghobrial explains precursor conditions for hematologic malignancies, and how the new Center for Prevention of Progression aims to help patients manage these conditions and prevent progression to blood cancers.